What is the main purpose of this 8-K filing?

This 8-K filing announces that Bristol-Myers Squibb has signed a definitive merger agreement to acquire MyoKardia, Inc. It details the terms of the proposed tender offer and provides information on where investors can find more details.

When will the tender offer begin?

The tender offer has not yet commenced. Bristol-Myers Squibb will file a tender offer statement on Schedule TO with the SEC when it is ready to begin the offer.

Are there any risks associated with this acquisition?

Yes, Bristol-Myers Squibb acknowledges that there are inherent risks and uncertainties in any acquisition, including the possibility that the deal may not be completed, may not close within the anticipated timeframe, or that the expected benefits may not be realized. Risks related to drug development are also noted.

BRISTOL MYERS SQUIBB CO 8-K SEC Disclosure

Q: What is the price Bristol-Myers Squibb is offering for MyoKardia shares?

Bristol-Myers Squibb is offering to acquire all outstanding shares of MyoKardia for $225.00 per share, to be paid in cash.

Summary

Bristol-Myers Squibb Company (BMY) announced on October 5, 2020, that it has entered into a definitive merger agreement to acquire MyoKardia, Inc. The agreement outlines a tender offer where Bristol-Myers Squibb's subsidiary, Gotham Merger Sub, Inc., will seek to acquire all outstanding shares of MyoKardia for $225.00 per share in cash. This strategic acquisition aims to bolster Bristol-Myers Squibb's cardiovascular portfolio and pipeline. Investors should note that the tender offer has not yet commenced, and full details will be provided in subsequent filings with the SEC. The company emphasizes that while this acquisition presents potential benefits, there are inherent risks and uncertainties associated with drug development and the completion of the transaction itself.

Key Highlights

1Bristol-Myers Squibb to acquire MyoKardia, Inc. through a tender offer.
2The proposed acquisition price is $225.00 per share in cash.
3The transaction is structured as a definitive merger agreement.
4The acquisition is expected to enhance Bristol-Myers Squibb's cardiovascular franchise.
5The tender offer has not yet commenced.
6Investors are advised to review SEC filings for detailed information regarding the tender offer.
7The company acknowledges risks and uncertainties associated with the acquisition and drug development.

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Oct 5, 2020)

Summary

Key Highlights

Frequently Asked Questions